Phase 3 Study of Adjuvant Regorafenib vs. Placebo for Patients with Stage 4 colorectal cancer
Diseases and Conditions Researched
Colon; Liver; Rectum
What is the purpose of this trial?
The objective of this study is to evaluate and compare the efficacy and safety of regorafenib vs. placebo in subjects with colorectal cancer after curative resection of liver metastasis and completion of all planned chemotherapy.
Click here for detailed participation information for this trial.
|Sponsor:||Bayer Healthcare Pharmaceuticals, Inc.|
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.